Építés alatt – nem éles oldal
Belépés
Leállítva2/3. fázis

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

A legfontosabb adatok

Ki végzi
Boehringer Ingelheim
Hol
Charleston, New Haven, Norfolk és Rancho Santa Margarita (Egyesült Államok)Mind a 4 helyszín megnézéseMég 13 másik országban, 24 helyszínen
Azonosító
Állapot
Leállítva
Fázis
2/3. fázis
Résztvevők
43 fő vett részt
Kezdés
2023. jún. 12.
Befejezés
2025. júl. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Spesolimab - solution for infusion
  • Placebo matching to spesolimab - solution for infusion
  • Spesolimab - solution for injection
  • Placebo matching to spesolimab - solution for injection
A regiszteradat frissítve
2026. március 12.

Ki vehet részt

Életkor
12 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female patients, aged 12 years and older (weight minimum is 35kg)
  • Confirmed diagnosis of Netherton syndrome (NS) (causative SPINK5 mutations) at baseline (Visit 2)
  • At least moderate severity of erythema at baseline (visit 2) (Ichthyosis Area Severity Index (IASI) score ≥ 16 and IASI-Erythema (E) score ≥8) and ≥ 3 on Investigator Global Assessment (IGA) score
  • Signed and dated written informed consent and assent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission in the trial
  • Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the clinical trial protocol (CTP) as well as in the patient, parent(s) (or patient's legal guardian) information

Ki nem vehet részt

  • Patients who have used topical corticosteroids (medium to high, US class I-V), topical retinoids, topical calcineurin inhibitors or keratolytics within 1 week prior to randomisation
  • Patients who have used emollient on the area to be biopsied in the previous 24 hours
  • Patients who have used systemic retinoids, other systemic immunosuppressants, systemic corticosteroids or phototherapy within 4 weeks prior to randomisation
  • Patients who have used systemic antibiotics within 2 weeks prior to randomisation
  • Patients who have received live vaccines within 4 weeks prior to randomisation
  • Patients who have received investigational products, biologics or immunoglobulins within 4 weeks or 5 half-lives (whichever is longer) prior to randomisation
  • Patients who have any prior exposure to BI 655130 or another interleukin 36 receptor (IL-36R) inhibitor biologics
  • Severe, progressive, or uncontrolled hepatic disease, defined as >3-fold Upper Limit of Normal (ULN) elevation in Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) or alkaline phosphatase, or >2-fold ULN elevation in total bilirubin
  • Further exclusion criteria apply

Helyszínek itt: Egyesült Államok

Még 13 másik országban, 24 helyszínen

  • Medical University of South CarolinaCharleston, Egyesült Államok
  • Yale University School Of MedicineNew Haven, Egyesült Államok
  • Virginia Clinical Research, Inc.Norfolk, Egyesült Államok
  • Mission Dermatology CenterRancho Santa Margarita, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years or older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS.

A teljes eredeti leírásKevesebb

Participants are divided into a spesolimab and a placebo group. Placebo injections look like spesolimab injections but do not contain any medicine. Every participant has a 2 in 3 chance of being in the spesolimab group. In the beginning, participants get the study medicine as an injection into a vein. Afterwards, they get it as an injection under the skin every month.

After 4 months, participants in the placebo group switch to spesolimab treatment.

Participants are in the study for up to 3 years. During this time, they visit the study site up to 42 times. The doctors regularly check participants' NS symptoms. The results are compared between the groups to see whether spesolimab works. The doctors also regularly check participants' general health and take note of any unwanted effects.

A vizsgálat 2 csoportja

  • PlaceboPlacebo, összehasonlításként

    Kezelés: Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection és Placebo matching to spesolimab - solution for injection

  • SpesolimabA vizsgált kezelés

    Kezelés: Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion és Spesolimab - solution for injection

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
EvasayilTM : A Placebo-controlled Trial to Evaluate the Efficacy and Safety of Spesolimab in the Treatment of Patients With Netherton Syndrome
A regiszteradat frissítve
2026. március 12.